In cancers such as lung cancer, gastric cancer, colorectal cancer, glioblastoma, and prostate cancer, HMGCR is often highly expressed, and this high expression correlates with poorer overall survival in patients (23–25). This evidence concerns the gene HMGCR and prostate cancer.